Journals / Klimik Dergisi / 2015 / Cilt: 28 - Sayı: 3

Risk Factors for Bloodstream Infections Due to Acinetobacter spp.: A Prospective Case-Control Study

Acinetobacter Türlerine Bağlı Kan Dolaşımı İnfeksiyonlarında Risk Faktörleri: İleriye Dönük Bir Olgu-Kontrol Çalışması

Pages
103–107
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Case group comprising patients with Acinetobacter bacteremia and control group 1 comprising patients with bacteremia due to other agents and control group 2 comprising non-bacteremic patients were compared in terms of demographic characteristics, underlying diseases, invasive procedures, and antibiotic use.Results: The study group (n=23) and control groups (n=46) were compared with univariate analysis and significant risk factors for Acinetobacter bacteremia were as follows: total parenteral nutrition, chemotherapy, use of broad spectrum antibiotics including ?-lactam and ?-lactamase inhibitors, carbapenems, teicoplanin, and antifungals (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this prospective case control study was to describe the risk factors for bacteremia due to Acinetobacter species among hospitalized patients.Methods: The study was conducted prospectively from July 2012 to January 2014, and one case group and two control groups were created.
📊
Key Findings & Data:Objective: The aim of this prospective case control study was to describe the risk factors for bacteremia due to Acinetobacter species among hospitalized patients.Methods: The study was conducted prospectively from July 2012 to January 2014, and one case group and two control groups were created.
💡
Conclusion & Impact:Case group comprising patients with Acinetobacter bacteremia and control group 1 comprising patients with bacteremia due to other agents and control group 2 comprising non-bacteremic patients were compared in terms of demographic characteristics, underlying diseases, invasive procedures, and antibiotic use.Results: The study group (n=23) and control groups (n=46) were compared with univariate analysis and significant risk factors for Acinetobacter bacteremia were as follows: total parenteral nutrition, chemotherapy, use of broad spectrum antibiotics including ?-lactam and ?-lactamase inhibitors, carbapenems, teicoplanin, and antifungals (p
🔬Design:Research Article
📍Scope:2012 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of this prospective case control study was to describe the risk factors for bacteremia due to Acinetobacter species among hospitalized patients.Methods: The study was conducted prospectively from July 2012 to January 2014, and one case group and two control groups were created. Case group comprising patients with Acinetobacter bacteremia and control group 1 comprising patients with bacteremia due to other agents and control group 2 comprising non-bacteremic patients were compared in terms of demographic characteristics, underlying diseases, invasive procedures, and antibiotic use.Results: The study group (n=23) and control groups (n=46) were compared with univariate analysis and significant risk factors for Acinetobacter bacteremia were as follows: total parenteral nutrition, chemotherapy, use of broad spectrum antibiotics including ?-lactam and ?-lactamase inhibitors, carbapenems, teicoplanin, and antifungals (p

Özet

Amaç: Bu ileriye dönük olgu-kontrol çalışmasında Acinetobacter türleriyle gelişen bakteriyemiler için risk faktörlerinin belirlenmesi amaçlanmıştır.Yöntemler: Temmuz 2012-Ocak 2014 tarihleri arasında ileriye dönük olarak yürütülen çalışmada bir olgu ve iki kontrol grubu oluşturulmuştur. Olgu grubunda Acinetobacter bakteriyemisi olan hastalar yer almıştır. Kontrol grubu 1'e, kan kültüründe Acinetobacter dışı bakteri üremesi olan ve bakteriyemik olarak değerlendirilen hastalar; kontrol grubu 2'ye, kan kültüründe herhangi bir üremesi olmayan ve bakteriyemik olmadığı bilinen hastalar dahil edilmiştir. Bulgular: Tek değişkenli analizde olgu grubuyla (n=23) kontrol grupları (n=46) karşılaştırıldığında, olgu grubunda total parenteral besleme, kemoterapi alma oranı, ?-laktam/?-laktamaz inhibitörü, karbapenem, teikoplanin ve antifungal kullanımı, kontrol gruplarına göre daha yüksek orandaydı ve anlamlı birer risk faktörü oldukları saptandı (p

🔖

Cite This Article

UÇAR, M., KALELİ, İ., KUTLU, M. (2022). Risk Factors for Bloodstream Infections Due to Acinetobacter spp.: A Prospective Case-Control Study. Klimik Dergisi, Cilt: 28 - Sayı: 3, 103–107. https://ajindex.com/articles/573613

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (4)

  1. Antunes LC, Visca P, Towner KJ. Acinetobacter baumannii: evolution of a global pathogen. Pathog Dis. 2014; 71(3): 292- 301. [CrossRef] De Gregorio E, Roscetto E, Iula VD, et al. Development of a real-time PCR assay for the rapid detection of Acinetobacter baumannii from whole blood samples. New Microbiol. 2015; 38(2): 251-7.
  2. Tigen ET, Koltka EN, Dogru A, Orhon ZN, Gura M, Vahaboglu H. Impact of the initiation time of colistin treatment for Acinetobacter infections. J Infect Chemother. 2013; 19(4): 703-8. [CrossRef] Jang TN, Lee SH, Huang CH, Lee CL, Chen WY. Risk factors and impact of nosocomial Acinetobacter baumannii bloodstream infections in the adult intensive care unit: a case-control study. J Hosp Infect. 2009; 73(2): 143-50. [CrossRef] Sheng WH, Liao CH, Lauderdale TL, et al. A multicenter study of risk factors and outcome of hospitalized patients with infections due to carbapenem-resistant Acinetobacter baumannii. Int J Infect Dis. 2010; 14(9): e764-9. [CrossRef] Baran G, Erbay A, Bodur H, et al. Risk factors for nosocomial imipenem-resistant Acinetobacter baumannii infections. Int J Infect Dis. 2008; 12(1): 16-21. [CrossRef] Tünger Ö, Keleş G, Şebnem Ş, et al. Risk factors for nosocomial Acinetobacter bacteremia: a case-control study of intensive care unit patients. Journal of Microbiology and Infectious Diseases. 2013; 3(4): 157-62. [CrossRef] Anunnatsiri S, Tonsawan P. Risk factors and clinical outcomes of multidrug-resistant Acinetobacter baumannii bacteremia at a university hospital in Thailand. Southeast Asian J Trop Med Public Health. 2011; 42(3): 693-703.
  3. Lee HY, Chen CL, Wu SR, Huang CW, Chiu CH. Risk factors and outcome analysis of Acinetobacter baumannii complex bacteremia in critical patients. Crit Care Med. 2014; 42(5): 1081-8. [CrossRef] Huang ST, Chiang MC, Kuo SC, et al. Risk factors and clinical outcomes of patients with carbapenem-resistant Acinetobacter baumannii bacteremia. J Microbiol Immunol Infect. 2012; 45(5): 356-62. [CrossRef] Balcı M, Bitirgen M, Kandemir B, Türk Arıbaş E, Erayman İ. Nozokomiyal Acinetobacter baumannii enfeksiyonlarında imipenem direnci ile ilişkili risk faktörleri. Nobel Medicus. 2012; 8(3): 24-31.
  4. Dizbay M, Guzel Tunccan O, Ergut Sezer B, Hizel K. Nosocomial imipenem-resistant Acinetobacter baumannii infections: epidemiology and risk factors. Scand J Infect Dis. 2010; 42(10): 741-6. [CrossRef] García-Garmendia JL, Ortiz-Leyba C, Garnacho-Montero J, et al. Risk factors for Acinetobacter baumannii nosocom